DE60209345D1 - Leporipox-basierende vektorvakzine - Google Patents

Leporipox-basierende vektorvakzine

Info

Publication number
DE60209345D1
DE60209345D1 DE60209345T DE60209345T DE60209345D1 DE 60209345 D1 DE60209345 D1 DE 60209345D1 DE 60209345 T DE60209345 T DE 60209345T DE 60209345 T DE60209345 T DE 60209345T DE 60209345 D1 DE60209345 D1 DE 60209345D1
Authority
DE
Germany
Prior art keywords
virus
lepori
exogenous dna
host
recombinant leporipox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60209345T
Other languages
English (en)
Other versions
DE60209345T2 (de
Inventor
Norman Spibey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel NV filed Critical Akzo Nobel NV
Application granted granted Critical
Publication of DE60209345D1 publication Critical patent/DE60209345D1/de
Publication of DE60209345T2 publication Critical patent/DE60209345T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60209345T 2001-03-08 2002-03-07 Leporipox-basierende vektorvakzine Expired - Lifetime DE60209345T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01200869 2001-03-08
EP01200869 2001-03-08
PCT/EP2002/002858 WO2002072852A2 (en) 2001-03-08 2002-03-07 Leporipox-based vector vaccines

Publications (2)

Publication Number Publication Date
DE60209345D1 true DE60209345D1 (de) 2006-04-27
DE60209345T2 DE60209345T2 (de) 2006-08-03

Family

ID=8179978

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60209345T Expired - Lifetime DE60209345T2 (de) 2001-03-08 2002-03-07 Leporipox-basierende vektorvakzine

Country Status (17)

Country Link
US (1) US6942864B2 (de)
EP (1) EP1370668B1 (de)
JP (1) JP4037273B2 (de)
CN (1) CN1258596C (de)
AT (1) ATE318321T1 (de)
AU (1) AU2002304856B2 (de)
BR (1) BR0207761A (de)
CA (1) CA2439872C (de)
DE (1) DE60209345T2 (de)
DK (1) DK1370668T3 (de)
ES (1) ES2258628T3 (de)
MX (1) MXPA03007862A (de)
NO (1) NO331305B1 (de)
NZ (1) NZ527940A (de)
PT (1) PT1370668E (de)
WO (1) WO2002072852A2 (de)
ZA (1) ZA200306607B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ572893A (en) * 2006-06-01 2011-06-30 Robarts Res Inst Myxoma virus mutants for cancer treatment
KR100831536B1 (ko) * 2007-01-19 2008-05-22 리엔 창 일렉트로닉 엔터프라이즈 컴퍼니 리미티드 풀 브릿지 드라이버
KR100831537B1 (ko) * 2007-01-19 2008-05-22 리엔 창 일렉트로닉 엔터프라이즈 컴퍼니 리미티드 하프 브릿지 드라이버
FR2925067B1 (fr) * 2007-12-18 2010-01-15 Agronomique Inst Nat Rech Vecteurs vaccinaux derives de leporipoxvirus
WO2021202971A1 (en) * 2020-04-02 2021-10-07 Arizona Board Of Regents On Behalf Of Arizona State University Covid-19 vaccine based on the myxoma virus platform
CN111904981A (zh) * 2020-09-07 2020-11-10 威世药业（如皋）有限公司 一种痘苗病毒致炎兔皮生产方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
AU2347692A (en) 1991-07-09 1993-02-11 Cornell Research Foundation Inc. Recombinant viral vaccine
TW377373B (en) 1993-09-22 1999-12-21 Wyeth Corp Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof
FR2736358B1 (fr) 1995-07-05 1997-09-26 Agronomique Inst Nat Rech Virus myxomateux recombinant
AU4266597A (en) * 1996-09-11 1998-04-14 General Hospital Corporation, The Use of a non-mammalian dna virus to express an exogenous gene in a mammalian cell
US6127172A (en) * 1998-05-29 2000-10-03 University Of Florida Materials and methods for delivery and expression of heterologous DNA in vertebrate cells
ES2153284B1 (es) * 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
US6294176B1 (en) * 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species

Also Published As

Publication number Publication date
CA2439872C (en) 2009-12-15
CN1258596C (zh) 2006-06-07
DE60209345T2 (de) 2006-08-03
CA2439872A1 (en) 2002-09-19
EP1370668A2 (de) 2003-12-17
BR0207761A (pt) 2006-01-31
MXPA03007862A (es) 2004-05-24
NO20033912D0 (no) 2003-09-04
EP1370668B1 (de) 2006-02-22
US6942864B2 (en) 2005-09-13
WO2002072852A3 (en) 2002-12-27
US20040137599A1 (en) 2004-07-15
AU2002304856B2 (en) 2006-08-24
JP2004528833A (ja) 2004-09-24
NO20033912L (no) 2003-10-22
JP4037273B2 (ja) 2008-01-23
NZ527940A (en) 2005-01-28
ES2258628T3 (es) 2006-09-01
WO2002072852A2 (en) 2002-09-19
DK1370668T3 (da) 2006-06-06
NO331305B1 (no) 2011-11-21
CN1527883A (zh) 2004-09-08
ZA200306607B (en) 2005-02-23
ATE318321T1 (de) 2006-03-15
PT1370668E (pt) 2006-06-30

Similar Documents

Publication Publication Date Title
EA200900180A1 (ru) Рекомбинантный модифицированный вирус осповакцины анкара (mva), экспрессирующий гомологичные последовательности, встроенные в поксвирусный геном
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
WO2008039408A3 (en) Live bacterial vaccines for viral infection prophylaxis or treatment
FI931309A0 (fi) Viralt bristfaelligt vaccin, som har producerats med en transkomplementerande cellinie
ATE447967T1 (de) Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
MXPA05009580A (es) Vacuna contra el virus de la influenza.
NZ627888A (en) Materials and methods for respiratory disease control in canines
MX2022010588A (es) Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2.
BRPI0512421A (pt) recombinantes de avipox expressando genes do vìrus da doença febre aftosa
DE50206472D1 (de) Attenuierte lebendimpfstoffe
JP2014507146A5 (de)
BRPI0816134A2 (pt) Herpesvírus, sequência de dna, vetor, célula, vírus, método para produção de partículas infecciosas, partículas infecciosas, vacina, uso de herpesvírus ou da sequência de dna ou do vetor ou das partículas infecciosas, e, método para o tratamento preventivo e/ou terapêutico de uma doença.
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
DK1425404T3 (da) Vaccinia-MVA-E3L-mutanter og anvendelse deraf
AU2014232363A8 (en) Foot and mouth disease virus (FMDV) consensus proteins, coding sequences therefor and vaccines made therefrom
ES2608627T5 (es) Uso de un poxvirus modificado para inducción rápida de inmunidad frente a un poxvirus u otros agentes infecciosos
EP2552490A4 (de) Ektodomänen des influenza-matrix-2-proteins, expressionssystem dafür und verwendungen davon
ATE318321T1 (de) Leporipox-basierende vektorvakzine
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
TW200734463A (en) Marked bovine viral diarrhea virus vaccines
PH12018502460A1 (en) Arthrogenic alphavirus vaccine
BR0310020A (pt) Expressão de genes no vìrus da vacìnia modificado ancara por uso do promotor de ati de vacìnia
WO2004009763A3 (en) Use of vaccinia virus deleted for the e3l gene as a vaccine vector
WO2003080112A3 (en) Imidazoquinolineamines as adjuvants in hiv dna vaccination
CR11537A (es) Vacuna

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: INTERVET INTERNATIONAL B. V., AN BOXMEER, NL